On July 20, 2022, Intervacc AB (publ) announced that the company has received an order for the equivalent of approximately SEK 3 million from Dechra Pharmaceuticals PLC Group. The order concerns the delivery of Strangvac®, a vaccine against the highly contagious and serious infectious disease equine strangles, which is endemic across Europe. The order, which contains vaccine vials for regions including the UK, Germany and France, is for delivery during July 2022 and used for launch in selected European countries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.16 SEK | -0.63% | -4.24% | -50.08% |
May. 15 | Intervacc AB Announces Board Appointments | CI |
May. 15 | Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-50.08% | 23.05M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- IVACC Stock
- News Intervacc AB
- Intervacc AB Receives Order for Strangvac, from the Dechra Pharmaceuticals plc Group for Launch in Selected European Countries